Indication
For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Medicine details
- Medicine name:
- ublituximab (Briumvi)
- SMC ID:
- SMC2731
- Pharmaceutical company
- Neuraxpharm UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Publication due date:
- 13 January 2025